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NanoViricides, Inc. is a publicly traded company (stock symbol: NNVC, OTC).   
 
This is not an offering memorandum and should not be construed as such.  
It is provided as a non-confidential document for informational purposes only. 
 
NanoViricides, Inc.(www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials 
for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped 
virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 
“swine flu”, H5N1 bird flu, seasonal Influenza, HIV, EKC, Herpes “cold sores” and genital Herpes, Hepatitis C, Rabies, 
Dengue fever, and Ebola virus, among others.  
 
This document contains forward-looking statements that reflect the current expectation of  NanoViricides, Inc. (the 
"Company) regarding future events. Actual events could differ materially and substantially from those projected herein and 
depend on a number of factors. Certain statements are “forward-looking statements” within the meaning of Section 27A of the 
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on 
forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some 
cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, 
performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking 
statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these 
forward-looking statements, even if new information becomes available in the future. Important factors that could cause 
actual results to differ materially from the company's expectations include, but are not limited to, those factors that are 
disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the 
United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or 
identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a 
nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory 
approvals, including with respect to the indications we are seeking; the successful commercialization of our product 
candidates; and market acceptance of our products. 
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Overview 
NanoViricides Today 
Technology 
NanoViricides® Product Pipeline 
Milestones & Future Objectives 
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Our Current Drug Programs 
Post-Discovery 
EBV 
RSV,  
Chikungunya, 
Rotavirus... 
Hepatitis C 
Ebola, 
Marburg, 
Rift Valley Fever, 
Hemorrhagic 
Viruses 
Rabies 
HIV 
Oral & Genital Herpes 
(“Cold Sores”)  
 
EKC Causing  
Adenovirus 
Pre-clinical Leads 
* FluCide™ one Drug 
for All Influenzas 
* Eye Drops for All Viral 
Conjunctivitis/Keratitis 
* Skin Cream & Gel for Oral, 
Genital Cold Sores 
* HIVCide™ Potentially 
“Functional Cure” 
* Dengue nanoviricide -avoid 
ADE Effect 
Dengue Virus,  
West Nile Virus,  
Yellow Fever Virus,  
Jap. Encephalitis Virus 
Influenzas 
H5N1 Bird Flu 
H7N, H9N, High Path 
Avian Influenzas 
 
Epidemic H1N1 
“Swine Flu” 
 
Seasonal Influenzas 
NOW ORAL!  
pre-IND 
HSV 
Broad Drug Pipeline Advancing Rapidly... 
Pre-IND Meeting Held with US FDA for Influenza, March 2012 
Sustained Activity 
“Functional Cure?” 
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Designing NanoMedicines  WHY ☞ Imperatives of Drug Development :  
‣ More Effectiveness 
‣ Greater Safety - Minimize Side Effects 
• Off-Target Activity, On-Target Activity, Metabolic Effects, Other 
‣ Patient Compliance  => Ideal: Treat only once☺ 
 HOW ☞ Divide and Rule aka Componentize Responsibilities  
‣ Greater Control by Design 
‣ Select Route of Administration 
• Injectables, Eye Drops, Skin Creams, In situ Patches/Depots,  
• Oral ??  
‣ Define Time Profile of Activity  
• Sustained Release, Controlled Release, Pulse-on-Demand, etc  
‣ Enable Site-Specific Delivery 
• Passively - eg EPR effect, BBB effect, Lipid partitioning, etc 
• ACTIVELY : Select Cell Type/Subtype, Virus, Bacteria, Parasite, Toxin… 
‣ Separation of Efficacy from Time-Profile and Delivery Responsibilities 
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NanoViricides Technology 
  Unique, Novel Platform enables: 
 
Novel Mechanism of Action 
Novel Class of Drugs - First-In-Class 
 
with extremely high efficacy levels and excellent 
safety 
 
Defining A New Plateau of Antiviral  Therapeutics  
 
based on TheraCour®  Platform Technology 
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What is a NanoViricide®? 
FIND the enemy... 
Ligands 
Target Virus Particle 
 
“Guided Missile” 
API’s 
Active Pharmaceuticals 
can be Encapsulated in the 
“Belly” of the nanoviricide 
 
Future Drugs -  
Creating Cures? 
ENCAPSULATE enemy... 
“Nanomicelle” 
A folded-up glob that can unfold and 
spread onto the virus particle after 
ligands bind to the virus 
 
“Attack from all around” 
DESTROY the enemy... 
“Nanoviricide” 
The virus thinks it bound to a host cell, 
starts its own unfolding machinery,  
destroying itself in the process 
 
Tricking the Virus 
Innovation... 
Slide 
 © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NNVC) 
8 
A nanoviricide® is a Cell Mimic  
“passive view” 
A nanoviricide “Looks Like” a Human Cell to the Virus 
A nanoviricide is large enough for a virus particle to latch onto it. 
Yet small enough to circulate readily in the body.   
 
Rather than the virus particle entering into a nanoviricide,  
a nanoviricide wraps around the virus particle and encapsulates it,  
by using the virus particle’s very same ability to enter a cell. 
HIV Particle  
binding to a Cell via CD4 
and a Coreceptor 
gp120 on virus 
(binds CD4, CCR5 
and CXCR4 on the 
Cell) 
CD4 on Cell 
The Cell 
CCR5 
CD4 “Key” that 
binds to HIV 
CCR5 “Key” that 
binds to HIV 
Make Ligands to Mimic 
the “Keys” 
Slide 
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A NanoViricide® Attacking a Virus Particle: 
Unique, Novel, Nanotech Design 
A single nanoviricide micelle may be capable of completely engulfing a Virus Particle.   Nanoviricide micelles self-assemble from 
multiple chains.  A single chain micelle shown for convenience. Illustration not to scale.  
Schematic Diagram Not Intended to be Construed as the In Vivo Mechanism 
Nanoviricides Dismantling MCMV Virus Particle 
Control Treated 
A 
C 
Virus Dismantled;  
Capsids Spilling Out  
A: intermediate state;  
C: total dismantling 
MCMV Virus Particle  
Containing Multiple Capsids 
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FluCide™ Against All Influenzas 
Successful Clinical Lead Development 
 Very first Animal Study Resulted in a Drug Candidate almost 8X 
Superior to Oseltamivir in Viral Load Reduction 
 1,000X Greater Viral Load Reduction, and equally impressive superior 
efficacy using other parameters, compared to Oseltamivir in same 
highly lethal animal model achieved... 
 Only 4 SAR Cycles Later 
 Chemistry, Manufacturing & Controls (CMC) Studies in Progress 
 cGMP Manufacturing Related Studies in Progress 
 First pre-IND Meeting held with US FDA in March, 2012 
 NEW: Orally Effective FluCide™ Drug Candidates Developed! 
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Oral vs IV FluCide Study 
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Protocol: Infection: Aerosol, 1M viral particles H1N1/A/WS/33 at t=0h, Booster infection Repeat at t=22h. 
Treatment start at t=24h. IV Treatment is once every 48h. Oral Treatment is 1X Daily at 3X dose of IV. 
Oseltamivir is 2X Daily at total 40mg/kg/d. Control is Infected untreated. 
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NV593422-IV NV593423-IV Oseltamivir 
NV593422-PO NV593423-PO Control 
3-PO 3-IV 2-IV 2-PO 
±7.5 
±4.6 
±5.2 
±3.9 ±4.6 
±1.0 
Oral Anti-Influenza Nanoviricides are  
As Effective as IV administration, and  
Substantially Superior to Oseltamivir 
in Increased Survival 
in a Highly Lethal Animal Model 
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NV5-2 IV 
NV5-3 IV 
NV5-4 IV  
(Saline Blind) 
NV5-2’ PO 
NV5-3’ PO Saline PO 
Saline IV 
Oseltamivir Untreated 
Oral Anti-Influenza Nanoviricides are  
As Effective as IV administration, and  
Substantially Superior to Oseltamivir 
in Decreased Lung Viral Load 
in a Highly Lethal Animal Model 
First Ever Oral 
Nanomedicine! 
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IV FluCide Study 
IV Drug (Piggy-back Infusion) for  
Severely Ill Hospitalized Patients 
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FluCide™ Candidates Unquestionably Superior to Oseltamivir  
FluCide Probably The Most Effective Anti-Influenza Drug At Present 
Full Survival (>21d) upon FluCide Treatment in H1N1 Mice Lethality Study, 2011-01 
Indicates Full Clinical Recovery Even with High Path, Severe Influenzas, is Possible 
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FluCide™ Oseltamivir 
extended treatment 
Untreated Control 
±10.6 
±3.2   
±2.3 
21 d 
Compared to 
 
Only 8 Days Survival with Extended 
Oseltamivir Treatment 
5 days 100% Lethality Infection in 
Control Untreated Animals =>  
Full Lethality-Oriented Study 
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FluCide™ against Influenza  
>1,000-fold Lung Viral Load Reduction in NanoViricide 
Treated Animals  
Only <2-fold reduction with Oseltamivir in this  
Lethal Influenza Infection Study 
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4.5 Days (108h) Post-Infection 
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Anti-Influenza Nanoviricide SAR Improvements 
FluCide™ is Unquestionably Superior to Tamiflu® 
FluCide Could Be The Most Effective Anti-Influenza Drug At Present 
Full Survival (>21d) upon Treatment Achieved in  
Only 4 SAR Cycles 
H1N1 Mice Lethality Study 
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2009-10 2010-08 2011-01 Oseltamivir Control 
FluCide FluCide FluCide Extended Treatment 
SAR   Optimization 
20 Slide 
 © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NNVC) 
We Believe We Can  
Achieve Similar  
Substantial SAR Improvements  
Against Other Viral Diseases  
As Well 
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Adenoviral Epidemic 
Kerato-Conjunctivitis 
Simple EKC nanoviricide eye drops  
lead to  
quick and complete clinical resolution in  
well known rabbit model 
White Conjunctiva  Rapidly Restored by  
Nanoviricide Drug Candidate Treatment 
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Epidemic Kerato-Conjuntivitis (EKC) - 
Severe Pink Eye Disease 
Adenovirus 5 Animal Studies  
Negative Control Nanoviricide “R” 
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Dengue Virus ADE Model: Preliminary Survival Study 
Antibody-Challenged AG129 Ifn-/- Mice, D2S10 Infection  
Prof. Eva Harris Lab Results  
First Ever Drug 
with Survival! 
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Different HSV-1 Viruses Completely Inhibited  
in Several Different Cell Culture Studies 
 > 99.99% Reduction of HSV-1 McKrae Strain 
 
McKrae Strain important in Herpis Keratitis (External Eye) 
 
Almost Complete Inhibition of HSV-1 H129 Strain 
 
H129: Relevant for “Cold Sores”, a Highly Pathogenic Strain 
 
Skin Cream for HSV-1 oral, genital outbreaks 
 
Eye Drops against HSV Keratitis (Eye Disease)  
 
Can we create a single Eye Drop nanoviricide drug that works against 
Herpes Keratitis as well as Adenoviral Conjunctivitis (EKC) ? 
Cover ~99% eye viral infections with a single antiviral ?  
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Nanoviricide Treatment was >12X More  
effective than the HAART standard therapy 
in a SCID-hu Thy/Liv Mouse Model - Study#1 
Only 300mg/kg total HIVCide produced effect equal to or 
better than 4,100mg/kg HAART drugs load  
Viral load Reduction on nanoviricides treatment was 
equal to or better than that on HAART treated mice 
CD4+/CD8+ (human) T cells increased equal to or better 
than that on HAART treated mice 
Virus Particle count inside human T cells decreased to 
much smaller levels on nanoviricides compared to 
HAART treatment 
Potential “Functional Cure” for HIV/AIDS? 
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Sustained Reduction in HIV-1 Viral Load 
Even After Treatment Stopped 
in the SCID-hu Thy/Liv Mouse Model in Study #2 
NV-5B Trtmt 
1,200 
mg/kg 
HAART Trtmt 
4,800 
mg/kg 
Day 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
2
0 
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 
4
8 “Functional Cure” for HIV/AIDS? 
NV-5B Trtmt stopped at 20 days,  
yet antiviral effects lasted > 48 days!  
(Viral load, CD4+CD8+ DP Cells, Total T Cells) 
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NanoViricides: 
Beyond Immunotherapeutics! 
 Immunoglobulins, Antibodies : Standard Antiviral Treatments 
 NanoViricides are Designed to Neutralize the Virus Particle 
Completely and Dismantle it  
 Nanoviricides Do Not Depend Upon the Immune System to 
encapsulate and dismantle the virus, as antibodies do 
 Nanoviricides Strategy: Seek, Attach, Encircle and Destroy 
‣ Classic War Strategy! 
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Routes of Administration 
 Injectables                      ✔  
 IV Infusion                     ✔ 
Eye Drops                       ✔ 
Skin Cream                    ✔ 
Nasal Sprays                  ✔ 
Bronchial Sprays          ✔ 
 In Situ Depos/Gels        ✔ 
Oral                                  ✔  
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Future Milestones/ Objectives 
 pre-IND Meeting with FDA - March 2012 - DONE 
 Executable Product Development Plan for Influenza 
 Chemistry, Manufacturing & Controls Studies (ongoing) 
 Lab Production to ~200g scale (ongoing)  
 Assays Development 
 Safety/Toxicology Studies  
 Dose-Response Studies in Animal Models 
 cGMP Manufacturing Facility -> Design Phase 
 Clinical Scale Production Scale-up (~1 Kg scale) 
 Translation of Production to cGMP, Validation, etc. 
 IND Filing for Influenza 
 Continue SAR on HIVCide, EKCCide, HerpeCide, and DengueCide 
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NanoViricides: Strong Product PipeLine 
Disease Drug Candidates 
Efficacy - Cell Cultures  
Safety - Animals 
Efficacy - 
Animals 
IND-Enabling Studies 
Phase I, II, III, 
NDA 
  Primary (Commercially Important) Programs  
Influenza, Bird Flu* 
FluCide™ Clinical 
Candidate 
External Eye Viral Diseases EKC-Cide™ SAR 
HIV/AIDS 
HivCide™ SAR 
Nearing Completion 
Herpes Oral and Genital Identified 
Dengue Identified 
  Neglected Tropical Diseases Programs - Social Responsibility  
Rabies RabiCide™ SAR 
  Bio-Defense Programs  
Ebola/Marburg TBD 
ADIF™ Technology** ADIF-Base™-I 
*    Includes all highly pathogenic avian influenza (HPAI) viruses capable of causing severe human epidemics, such as H5N1, H7N, H9N.  
**  ADIF: “Accurate-Drug-In-Field” is NanoViricides, Inc. unique technology. The ADIF-Base nanomicelles can be stockpiled. When a novel infection (natural or bioterrorism) occurs, a 
nanoviricide against that virus can be quickly created in the field and used to stop an epidemic from spreading.  
We plan on obtaining non-equity funding for our NTD and Bio-defense programs. The Company believes that these programs benefit our commercially important drug development 
programs, and vice versa.   
The Regulatory Process is complex. A Tox Package needs to be developed for each drug candidate. Then an IND is submitted to the FDA. Human Clinical Trials, Phase I, II, and III, are 
conducted upon IND approval. An NDA is submitted after that. A drug can be marketed only after FDA approval. The Company cannot reliably predict timelines for these events, nor can it 
assure that it will be successful in developing any drugs.  
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Large Market Sizes:  
Strong ROI Opportunity 
Disease/Virus 
$ Billions, 2013 
estimates (1) 
HIV/AIDS $ 21 B     . 
HIV-Cide™ Potentially  
a “Functional Cure”  
Influenzas $ 7 B     . 
Resistance to Current Drugs widespread.  
FluCide™ as a Pan-Influenza Drug 
Eye Drops Antiviral $ 1~5 B (2) . No current non-toxic drugs 
Herpes “Cold Sores” 
Skin Cream & Gel 
$ 2 B     . Current therapies have limited effectiveness 
Hepatitis C $ 6 B     . Current therapies not very effective 
Dengue, Rabies, other 
NTD’s 
$ 1 B (2) . 
combined           
Rapidly increasing developing world 
markets not properly accounted for 
Ebola/Marburg/VHF 
$ 1 B     . 
combined           
Biodefense; Single customer issues 
Government Grants & Contracts 
(1). Jain Pharma Biotech. March 2009. “Antiviral Therapeutics: Technologies, Companies & Markets”, by Prof. K. K. Jain, MD, FRACS, FFPM. Basel, Switzerland.   
(2). Estimates based on the Jain Report, and a report commissioned by the Company for more detailed  analyses of these special markets. March 2009.  
>$20B if good 
prophylactic & 
therapeutic? 
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NanoViricides Executive Team 
Eugene Seymour, MD MPH 
CEO 
Founder, Saliva Diagnostic Systems (SDS)  
Took SDS Public 
Med. Dir., Center for AIDS Research, Inc.,  
A Public Charitable Trust 
Krishna Menon, VMD, PhD 
consulting CRO 
Scientist of the Year (1999) at Eli Lilly.  
Alimta(tm) Inventor. AZT Pre-clinicals.  
3 Blockbuster Drugs. 9 Major Drugs.  
7 Patents on Pharmaceuticals.  
Randall Barton, PhD 
CSO 
Former Director of In-Vitro Cardiovascular Research at 
Boehringer Ingelheim 
Nevirapine (Virammune™) Development 
 
Anil R. Diwan, PhD 
President & Chairman 
Co-Inventor of Nanoviricides™ Products &  
TheraCour ® Technologies 
Serial Entrepreneur, 19 years leadership  experience 
Key Patents, Several NIH SBIR Awards 
Jayant Tatake, PhD 
VP, R&D 
Former Assistant Director of Pharma.Analytics at 
InterPharm, Inc.  
Co-Inventor of Nanoviricides™ Products &  
TheraCour ® Technologies 
Synthesis to Scale-up, Pharmaceutical GMP 
Slide 
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The End 
